EUCTR2014-001581-10-IE进行中（未招募）不适用
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritus - Study of the Neurokinin-1 Receptor Antagonist VDP-737 in Subjects with Chronic Pruritus
Tigercat Pharma, Inc.0 个研究点目标入组 264 人开始时间: 2014年5月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females who are at least 18 years of age and no more than 65 years of age.
- •2. Willing and able to understand and sign informed consent.
- •3. Subjects must have pruritus of at least 6 weeks duration which is unresponsive or inadequately responsive to current therapies such as topical steroids or antihistamine therapy.
- •4. History of chronic pruritus that may be associated with inflammatory skin disease (such as stable atopic dermatitis, psoriasis, lichen planus, aestatotic dermatitis, prurigonodularis, lichen simplex chronicus, and pruritus of undetermined origin that underwent full work up) or may be independent of a primary skin disease pruritus .
- •5. Subject must have a baseline VAS pruritus score of at least 7, and must have a score of at least 7 on 2 or more of the last 3 available entries in the e-diary provided at Screening.
- •6. Female subjects must be of non-childbearing potential (ie, post-menopausal for at least 1 year, had a hysterectomy, or had a tubal ligation) or, if of childbearing potential, must have a confirmed negative urine pregnancy test prior to study treatment and be willing to use effective contraception for the duration of the trial. Effective contraception is defined as follows: oral/implant/injectable/ transdermal contraceptives, intrauterine device, condom with spermicide, or diaphragm with spermicide. Abstinence or partner’s vasectomy is acceptable if the female agrees to use effective contraception if she decides to discontinue abstinence or to have sexual intercourse with a non-vasectomized partner.
- •7. Judged to be in good health based upon the results of a physical examination, medical history, and safety laboratory tests.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have any medical condition or disability that would interfere with the assessment of safety or efficacy in this trial or would compromise the ability of the subject to undergo study procedures or to give informed consent.
- •2. Have a history of sensitivity to any components of the study material.
- •3. Are females of childbearing potential who are unwilling to use adequate contraception or who are breast feeding.
- •4. Have any chronic or acute medical condition that, in the opinion of the investigator, might interfere with the study results or place the subject at undue risk.
- •5. Have chronic renal disease, i.e., serum creatinine greater than 2 times the upper limit of normal.
- •6. Have chronic liver disease, i.e., AST or ALT greater than 2 times the upper limit of normal. Subjects with hepatitis B and C who have normal liver function may be enrolled.
- •7. Have a current malignancy (such as Hodgkin’s lymphoma, B or T cell lymphoma, or myeloma) or blood cell dyscrasia (eg, polycythemia ormyelofibrosis) that would lead to systemic chronic pruritus.
- •8. Subjects with untreated hyperthyroidism.
- •9. Have pruritus of psychogenicetiology (delusions of parasitosis, obsessive compulsive disorder and major depression) or neuropathic etiology (due to shingles, spinal cord injury or with neurologic deficit).
- •10. Have pruritus due to urticaria, drug allergy, or infection (such as pityriasisrosea or tinea or active human immunodeficiency virus [HIV]). Note: Subjects with HIV who have undetectable viral load, CD 4 counts >200 cells/cc, and stable retroviral therapy may enroll.
- •11. Are on medications known to cause pruritus, i.e. Erbitux®, opioids, cocaine, amphetamines, and angiotensin converting enzyme (ACE) inhibitors.
- •12. Have taken investigational medications within 30 days prior to Screening.
- •13. Are unwilling to discontinue specific pruritus medications for at least two weeks prior to initiation of study and throughout the study period.
- •14. Have a history (within the previous 1 month) of use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI),serotonin-norepinephrine reuptake inhibitors (SNRIS),monoamine oxidase (MAO) inhibitors, opioids, immune-modulators (e.g. azathioprine, methotrexate, mycophenolatemofetil, cyclosporine A, antibodies), or neuroactive medications (e.g. pregabalin, gabapentin).
- •15. Have a history (within the previous 1 month) of use of sedatives or tranquilizers. Subjects must undergo an appropriate washout period from any sedatives or tranquilizers before enrolling in the study.
- •16. Received ultraviolet B (UVB) or psoralen + ultraviolet A (PUVA) treatment within 30 days prior to Screening.
- •17. Within in the past 12 months, have expressed suicidal ideation with some intent to act.
- •18. Started or changed medications, creams, or emollients including over-the-counter (OTC) preparations or bath oil treatment for relief of pruritus within 7 days prior to Screening.
- •19. Have any social or medical condition (e.g. alcoholism, drug dependency, psychotic state) that, in the investigator’s opinion, might interfere with the subject’s ability to comply with the requirements of the protocol.
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort toEvaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients withActive Rheumatoid Arthritis Despite Methotrexate Therapyactive rheumatoid arthritisEUCTR2012-000439-17-GBMerck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)342
进行中（未招募）
不适用
A study comparing the combination of the best supportive care plus E7080 versus best supportive care alone, in patients with advanced lung cancer or lung cancer that has spread, who have been previously treated, unsuccessfully, with at least 2 different treatmentsocally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002347-10-CZEisai Inc.135
进行中（未招募）
不适用
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort toEvaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients withActive Rheumatoid Arthritis Despite Methotrexate Therapyactive rheumatoid arthritisEUCTR2012-000439-17-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.342
进行中（未招募）
不适用
A study comparing the combination of the best supportive care plusE7080 versus best supportive care alone, in patients with advanced lungcancer or lung cancer that has spread, who have been previouslytreated, unsuccessfully, with at least 2 different treatmentsocally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002347-10-ITEISAI INC.135
进行中（未招募）
1 期
A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune ThrombocytopeniaEUCTR2019-004103-12-BGTakeda Development Center Americas, Inc. (Takeda)54